Welcome to our dedicated page for Staar Surgical Co news (Ticker: STAA), a resource for investors and traders seeking the latest updates and insights on Staar Surgical Co stock.
Staar Surgical Co (NASDAQ: STAA) is a prominent player in the ophthalmic surgery market, with over three decades of experience. The company specializes in the development, manufacture, and marketing of implantable lenses and accompanying delivery systems for the eye. Staar Surgical's flagship product line includes the EVO Visian Implantable Collamer® Lenses (ICLs), which are used to treat a variety of visual disorders such as myopia, hyperopia, astigmatism, and presbyopia.
These lenses are designed to provide visual freedom to patients, significantly reducing or eliminating their reliance on glasses or contact lenses. The EVO Visian ICLs are foldable, allowing for a minimally invasive procedure where the lens is inserted through a small incision. This innovative approach not only enhances surgical outcomes but also minimizes recovery time for patients.
To date, nearly 600,000 EVO Visian ICLs have been implanted worldwide, showcasing the trust and effectiveness of Staar Surgical's products. Additionally, the company offers minimally invasive intraocular lenses (IOLs) geared towards cataract surgery. These include foldable IOLs and aspheric IOLs that deliver a clearer image compared to traditional spherical lenses.
Staar Surgical's commitment to advancing ophthalmic technology is evident in its continuous efforts to improve product offerings and expand its market reach. The company has formed strategic partnerships and collaborations to bolster its research and development initiatives, ensuring the delivery of cutting-edge solutions in eye care.
Financially, Staar Surgical has shown consistent growth, with the majority of its revenue generated from the ophthalmic surgical product segment. The company's focus remains on innovation and quality, driving its mission to enhance vision care globally.
STAAR Surgical Company (NASDAQ: STAA) has announced its participation in the 4th Annual BTIG Ophthalmology Day. The company's Chair of the Board, President and CEO, Thomas G. Frinzi, will engage in investor meetings and a fireside chat scheduled for December 2, 2024, at 4:00 p.m. ET. STAAR Surgical, with over 40 years in ophthalmic surgery, specializes in developing implantable lenses, particularly the EVO ICL™ product line for myopia, astigmatism and presbyopia. The company has sold more than 3,000,000 ICLs globally and markets these lenses in over 75 countries.
STAAR Surgical Company (NASDAQ: STAA) announces its participation in the upcoming Stephens Annual Investment Conference in Nashville. Chief Financial Officer Patrick F. Williams will participate in a webcast fireside chat on Wednesday, November 20, 2024, at 11:00 a.m. ET. STAAR Surgical, with over 40 years in ophthalmic surgery, specializes in developing implantable lenses, particularly the EVO ICL™ product line for myopia, astigmatism, and presbyopia. The company has sold more than 3,000,000 ICLs across 75+ countries and operates manufacturing facilities in California and Switzerland.
STAAR Surgical reported Q3 2024 financial results with net sales up 10% to $88.6 million, driven by growth across all regions: Americas (+14%), EMEA (+12%), and APAC (+9%). ICL sales increased 10% to $89.1 million with unit growth of 6%. The company achieved a gross margin of 77.3% and net income of $10.0 million ($0.20 per share), up from $4.8 million ($0.10 per share) year ago. The company maintained its fiscal year 2024 outlook with projected net sales of $340-345 million and Adjusted EBITDA of approximately $42 million.
STAAR Surgical reported strong Q3 2024 financial results with net sales up 10% to $88.6 million, driven by growth across all regions: Americas (+14%), EMEA (+12%), and APAC (+9%). The company achieved ICL sales of $89.1 million, also up 10% year-over-year, with unit growth of 6%. Net income reached $10.0 million ($0.20 per share), increasing from $4.8 million ($0.10 per share) in the previous year.
Despite a softening macroeconomic environment, particularly in China during the second half of the quarter, STAAR maintained its fiscal year 2024 outlook with projected net sales of $340-345 million and Adjusted EBITDA of approximately $42 million. The company ended the quarter with $236.0 million in cash, cash equivalents, and investments.
STAAR Surgical (NASDAQ: STAA) has announced it will release its third quarter 2024 financial results on Wednesday, October 30, 2024, after market close. The company will host an earnings webcast at 4:30 p.m. ET to discuss financial results and operational progress. STAAR Surgical specializes in ophthalmic surgery, designing and manufacturing implantable lenses including the EVO ICL™ product line. The company has sold over 3,000,000 ICLs and markets these lenses in more than 75 countries.
STAAR Surgical Company (NASDAQ: STAA) has announced the expansion and relocation of its STAAR Surgical Experience Center at its headquarters in Lake Forest, California. This state-of-the-art facility is designed to meet the growing demand for EVO ICL training among surgeons and refractive practices, driven by the increasing global myopia epidemic.
The center offers comprehensive, hands-on training and education in lens-based vision correction, featuring:
- Immersive wet lab training stations for up to 24 practitioners
- Advanced visualization and communication technology
- Stella™, STAAR's latest innovation in EVO ICL planning and ordering
- Demonstrations of advanced diagnostic technology
The expansion comes as STAAR Surgical reports a 25% growth in EVO ICL units in the U.S. in the first half of 2024, with more than 700 U.S. surgeons now certified to perform EVO ICL procedures. The company expects to sell more ICLs between 2024 and 2026 than in the first 25 years of ICL sales combined.
STAAR Surgical (NASDAQ: STAA) reported Q2 2024 financial results with record quarterly net sales of $99.0 million, a 7% increase from the previous year. In constant currency, sales reached $100.4 million, a 9% growth. The ICL sales grew by 7% to $99.4 million. The company achieved a gross margin of 79.2%, up from 76.6%. Net income was $7.4 million, or $0.15 per share, compared to $6.1 million, or $0.12 per share, last year. Adjusted EBITDA was $22.5 million, or $0.45 per share, up from $18.3 million, or $0.37 per share.
The company revised its fiscal 2024 outlook, now expecting net sales between $340 million and $345 million, and Adjusted EBITDA of approximately $42 million. Sales growth was notable in all key geographies, with U.S. sales up 25%, APAC up 6%, and EMEA up 10%.
Operating expenses rose to $66.5 million from $62.1 million, influenced by increased compensation and facilities costs. The company has $235.5 million in cash, cash equivalents, and investments as of June 28, 2024.
STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses (EVO ICL™), has announced its plans to release second quarter 2024 financial results on August 7, 2024, after market close. The company will host an earnings webcast at 4:15 p.m. ET / 1:15 p.m. PT on the same day to discuss financial results and operational progress. Investors can access the webcast through the company's website or a dedicated link. STAAR Surgical has been focused on ophthalmic surgery for over 40 years and has sold more than 3,000,000 ICLs in over 75 countries. The company operates manufacturing facilities in California and Switzerland.
STAAR Surgical Company (NASDAQ: STAA), a leading developer of the EVO family of Implantable Collamer® Lenses, announces its participation in the Canaccord Genuity 44th Annual Growth Conference in Boston. Patrick F. Williams, Chief Financial Officer, will engage in a fireside chat on August 13, 2024, at 8:30 a.m. Eastern Time. Investors and the public can access a live webcast of the event through STAAR's investor website.
STAAR Surgical, with over 40 years of focus on ophthalmic surgery, specializes in implantable lenses for visual freedom. Their EVO ICL™ product line has sold more than 3,000,000 ICLs globally, marketed in over 75 countries. The company operates facilities in California and Switzerland, continuing its commitment to innovative eye care solutions.
STAAR Surgical Company (NASDAQ: STAA), a leader in developing and marketing Implantable Collamer® Lenses (EVO ICL™) for myopia, astigmatism, and presbyopia, will participate in the Goldman Sachs 45th Annual Global Healthcare Conference.
Chief Financial Officer Patrick F. Williams will represent STAAR in a fireside chat on June 12, 2024, at 8:00 a.m. Eastern Time. The event will be webcast live, with a recording available on STAAR's investor website afterward.
STAAR has been dedicated to ophthalmic surgery for over 40 years, selling over 3 million ICLs in more than 75 countries. Headquartered in Lake Forest, CA, the company operates production facilities in the U.S. and Switzerland.
FAQ
What is the current stock price of Staar Surgical Co (STAA)?
What is the market cap of Staar Surgical Co (STAA)?
What does Staar Surgical Co specialize in?
What are EVO Visian Implantable Collamer Lenses (ICLs)?
How many EVO Visian ICLs have been implanted to date?
What are the main types of products offered by Staar Surgical Co?
What are the benefits of Staar Surgical's foldable lenses?
What financial segment contributes most to Staar Surgical's revenue?
What innovations have Staar Surgical introduced in cataract surgery?
How does Staar Surgical ensure the quality of its products?
What are the core markets for Staar Surgical's products?
What are some recent achievements of Staar Surgical?
